

DR-AI: AI in Diabetic Retinopathy Screening

Group 16:

Amirhasan Khoramroudi

Dayana Sianny Guillermo Ladera

Mahsa Samadi

Amani Yagob

Katreen Suleiman




Table of Contents

01

Introduction

02

Business Case

03

Current State



04

Future State

05

Stakeholders

06

Conclusion




01

Introduction

What is a Diabetic Retinopathy?

DIABETIC RETINOPATHY



Introduction and Background



Diabetic retinopathy affects 34.6% of diabetic patients, with early-stage cases often asymptomatic. Screening is vital, but global initiatives face challenges like healthcare professional shortages, infrastructure limitations, and costs (Rêgo et al., 2022).



The World Health Organization emphasizes the screening of all diabetes patients, particularly crucial as diabetes diagnoses rise and global life expectancy increases, necessitating swift adaptations in healthcare services to ensure widespread screenings (Rêgo et al., 2022).

02

Business Case



Traditional methods Vs. AI-driven CDSS



Current DR screening System


- Limited accessibility due to limited trained staff
- Cost-related issues
- Increased burden on healthcare resources
- Patient non-compliance
- Accurate screening methods



AI-driven CDSS – DR-AI

- Improved accessibility
- Cost-effective
- Reduce need for specialist visits.
- Patient compliance.
- Improved accuracy of screening

Risks and Mitigation Strategies:



Costs:

Risks: initial setup expenses, staff training, system development

Mitigation strategy: develop clear financial plan to save costs.



Technical Risks:

Risks: not maintaining efficient/updated AI system

Mitigation strategy: Perform regular maintenance and software updates, hiring IT development team.



Integration challenges:

Risks: problems with implementing the AI-CDSS withing the existing healthcare system, training of the medical staff, patient acceptance.

Mitigation strategy: train medical staff on the new system and educating patients through a comprehensive educational plan and highlighting the benefits and AI-driven screening



03

Current State

CURRENT STATE/ GAP ANALYSIS




**1. Performed by specialized care
(optometrists and ophthalmologists)**



2. Costly and time consuming



3. Long waiting times for screening




FLOW CHART: CURRENT STATE EXAMPLE

Actors involved:

- Patient
- Primary care physician
- Optometrist
- Ophthalmologist





Issues:

1. Specialized care
2. Waiting time for screening



CURRENT STATE WORKFLOW





POTENTIAL SOLUTION


CDSS – ARTIFICIAL INTELLIGENCE FOR SCREENING DR

- Artificial intelligence (AI) systems using digital fundus photography
- This can reduce the burden on the health system in detecting DR and offer timely detection of the stage of the disease to avoid blindness.



(Padhy et al., 2019)

INFOGRAPHIC



DR-AI: Diabetic Retinopathy Artificial Intelligence

Screening using mobile devices



Early detection can reduce the risk
of severe vision loss by 95%



Diabetes affects 8.9% or
over 3 million Canadians

What is DR?

Diabetic retinopathy is a disease
caused by high blood sugar levels that
damage the small vessels in the eye, in
people with type 1 or 2 diabetes.
It is the main cause of blindness
worldwide.

Barriers to DR screening



**Need for
specialised care
ophthalmologist
or physician**




**Long waiting
times for
screening**



**Current
process is
costly and
time-
consuming**

INFOGRAPHIC



HOW DOES DR-AI (CDSS) HELP?



1. Increasing the number of cases detected
2. Immediate referral of patients who require treatment
3. Deliver a more reliable and quick DR grading using convolution neural networks
4. Eliminate the necessity of attending hospital
5. Provide a more accurate prediction of DR development

HOW DOES DRAI WORK?

1. Patient diagnosed with type 1 or 2 diabetes



2. Go to Primary Care Center



3. Attended by a General Practitioner



4. Fundus photos are taken using AI through a mobile phone



5. DR grading System




6. Moderate to severe degree: the patient is referred to an ophthalmologist




04

Future State






Future State Map




Convolutional Neural Networks



CNN has made uncomplicated automated retinal image analysis possible


Uses features to classify input images based on the training set

Produce (feature) maps with high-level feature



Source: (Balodi, 2019)


Source: (Kim et al., 2022)




Retinal Images

Summarises features in the feature map created by convolution layer


Explanatory (X) AI and Transfer Learning




Source: (Madala, Suvarna, & Pranathi Jalapally, 2022)




Input Images




Source: (Kim et al., 2022)



Smaller Dataset




Transfer Trained
Weights



Source: (Bidwai, Gite, Pahuja, & Kotecha, 2022)

Electronic Health Record Integration



Source: (Remidio, n.d.)



Fundus camera-equipped
Smartphone


Source: (Madala, Suvarna, & Pranathi
Jalapally, 2022)



Input Images

Preprocessing

DR-AI



Source: (Hatice Öncel Çekim, Hatice Nur
Karakavak, Gamze Özel, & Tekin, 2023)

Medical History

Combine non-image data

XAI

Risk assessment, classification results and
visuals, and recommendation

Input images, classification results and visuals automatically
Saved into EHR

EHR

DR
screening/referral
guidelines

DR Screening and Referral Guidelines

Table 1: ICO/ADA 2018 DR Screening and Referral Guidelines for High Resource Settings

Source: (Lee, 2023)


Classification	Re-examination or Next Screening Schedule	Referral to Ophthalmologist
Diabetic Retinopathy (DR)		
No apparent DR, mild nonproliferative DR, and no DME	Re-examination in 1–2 yrs	Referral not required
Mild nonproliferative DR	6–12 mos	Referral not required
Moderate nonproliferative DR	3–6 mos	Referral required
Severe nonproliferative DR	<3 mos	Referral required
Proliferative DR	<1 mo	Referral required
Diabetic Macular Edema (DME)		
Non-center-involving DME	3 mos	Referral required
Center-involving DME	1 mo	Referral required

Table 2: ICO/ADA 2018 DR Screening Follow-up Guidelines for Low-Intermediate Resource Settings

Source: (Lee, 2023)

Classification	Re-examination or Next Screening Schedule	Referral to Ophthalmologist
Diabetic Retinopathy (DR)		
No apparent DR, mild nonproliferative DR, and no DME	Re-examination in 1–2 yrs	Referral not required
Mild nonproliferative DR	1–2 yrs	Referral not required
Moderate nonproliferative DR	6–12 mos	Referral required
Severe nonproliferative DR	<3 mos	Referral required
Proliferative DR	<1 mo	Referral required
Diabetic Macular Edema (DME)		
Non-center-involving DME	3 mos	Referral not required (referral recommended if laser sources available)
Center-involving DME	1 mo	Referral required

DR-AI Mobile App



DR-AI Website

DRAI

GRADE

CONNECTIVITY

HELP

HISTORY

SETTINGS

PRIVACY

John Doe

BEGIN ANALYSIS

IMAGES TRANSMITTED

PRE-PROCESSING

CLASSIFICATION

RISK ASSESSMENT

RESULTS

GRADING RESULTS:

!

RISK ASSESSMENT:

RECOMMENDATION:

View Classification Images

ANALYSIS SAVED INTO EHR

No/Mild/Moderate /Severe Non-proliferative DR, Proliferative DR

Low/Moderate/High Risk Based on Medical Records

Personalised Screening Plan Based on Risk Assessment and Guidelines, and/or Ophthalmology referral



05

Stakeholders

Stakeholder Engagement

- 1- Patients
 - 2- Primary Care Practice
 - 3- Ophthalmologists/Optometrists/Hospitals
 - 4- AI Developers
 - 5- Regulatory Authorities
 - 6- Research Organizations
 - 7- Health Informaticians
 - 8- EMR Vendors
 - 9- WHO
 - 10- Other CDSS system vendors
- (IST Project Management Office, 2023)



Inform

Consult

Engage

Collaborate

06

Conclusion



Next steps/Conclusion



AI-driven CDSS for DR screening Implementation

- Enhance the screening process for eye diseases
 - Primary care clinics
 - Diabetes centers
 - Ophthalmology clinics
- Pharmacies accessing healthcare professionals
- Health insurance companies
- Companies can include DR-AI



Future of AI-driven CDSS for DR screening (DR-AI)

AI algorithms and CDSS systems(DR-AI)

- Better detecting invisible signs of DR
- Integrating CDSS into healthcare systems
- Combining the tool with telemedicine platforms.
- Technology affordable and portable
 - Smaller clinics
 - Rural areas
 - Developing countries
- Addressing privacy and ethical concerns
- Test for a broader range of eye illnesses and diseases
- DR-AI mobile health apps-self-assessments

References

- Marcus, J. (2023, February 1). Addressing a blind spot in care for patients living with diabetes — Healthy Debate. <https://healthydebate.ca/2023/02/topic/blind-spot-care-diabetes/>,
<https://healthydebate.ca/2023/02/topic/blind-spot-care-diabetes/>
- Swersky, Z. C. & J. (2022). Evaluating guidelines for de-escalating care from ophthalmology to optometry in the context of diabetic retinopathy. *Diabetes Management*, 12(1), 299–306. [https://doi.org/10.37532/1758-1907.2022.12\(1\).299-306](https://doi.org/10.37532/1758-1907.2022.12(1).299-306)
- Padhy, S. K., Takkar, B., Chawla, R., & Kumar, A. (2019). Artificial intelligence in diabetic retinopathy: A natural step to the future. *Indian Journal of Ophthalmology*, 67(7), 1004. https://doi.org/10.4103/ijo.IJO_1989_18
- Cheung, N., Mitchell, P., & Wong, T. Y. (2010). Diabetic retinopathy. *The Lancet*, 376(9735), 124–136. [https://doi.org/10.1016/s0140-6736\(09\)62124-3](https://doi.org/10.1016/s0140-6736(09)62124-3)
- Tan, T.-E., & Wong, T. Y. (2023). Diabetic retinopathy: Looking forward to 2030. *Frontiers in Endocrinology*, 13. <https://doi.org/10.3389/fendo.2022.1077669>
- Bellefleur, V., Lim, G., Rim, T. H., Tan, G. S., Cheung, C. Y., Sadda, S., He, M., Tufail, A., Lee, M. L., Hsu, W., & Ting, D. S. (2019). Artificial Intelligence Screening for diabetic retinopathy: The Real-World Emerging Application. *Current Diabetes Reports*, 19(9). <https://doi.org/10.1007/s11892-019-1189-3>
- Rêgo, S., Monteiro-Soares, M., Dutra-Medeiros, M., Soares, F., Dias, C. C., & Nunes, F. (2022). Implementation and evaluation of a mobile retinal image acquisition system for screening Diabetic Retinopathy: Study Protocol. *Diabetology*, 3(1), 1–16. <https://doi.org/10.3390/diabetology3010001>
- Egunsola, O., Dowsett, L. E., Diaz, R., Brent, M. H., Rac, V., & Clement, F. M. (2021). Diabetic retinopathy screening: A systematic review of qualitative literature. *Canadian Journal of Diabetes*, 45(8). <https://doi.org/10.1016/j.jcjd.2021.01.014>

References

- Altomare, F., Kherani, A., & Lovshin, J. (2018). Retinopathy. *Canadian Journal of Diabetes*, 42. <https://doi.org/10.1016/j.jcjd.2017.10.027>
- Vashist, P., Gupta, N., Singh, S., & Saxena, R. (2011). Role of early screening for diabetic retinopathy in patients with diabetes mellitus: An overview. *Indian Journal of Community Medicine*, 36(4), 247. <https://doi.org/10.4103/0970-0218.91324>
- Vujosevic, S., Aldington, S. J., Silva, P., Hernández, C., Scanlon, P., Peto, T., & Simó, R. (2020). Screening for diabetic retinopathy: New perspectives and challenges. *The Lancet Diabetes & Endocrinology*, 8(4), 337–347. [https://doi.org/10.1016/s2213-8587\(19\)30411-5](https://doi.org/10.1016/s2213-8587(19)30411-5)
- Bellefleur, V., Lim, G., Rim, T. H., Tan, G. S., Cheung, C. Y., Sadda, S., He, M., Tufail, A., Lee, M. L., Hsu, W., & Ting, D. S. (2019). Artificial Intelligence Screening for diabetic retinopathy: The Real-World Emerging Application. *Current Diabetes Reports*, 19(9). <https://doi.org/10.1007/s11892-019-1189-3>
- Rêgo, S., Monteiro-Soares, M., Dutra-Medeiros, M., Soares, F., Dias, C. C., & Nunes, F. (2022). Implementation and evaluation of a mobile retinal image acquisition system for screening Diabetic Retinopathy: Study Protocol. *Diabetology*, 3(1), 1–16. <https://doi.org/10.3390/diabetology3010001>
- Egunsola, O., Dowsett, L. E., Diaz, R., Brent, M. H., Rac, V., & Clement, F. M. (2021). Diabetic retinopathy screening: A systematic review of qualitative literature. *Canadian Journal of Diabetes*, 45(8). <https://doi.org/10.1016/j.jcjd.2021.01.014>
- Arunkumar, R., & Karthigaikumar, P. (2015). Multi-retinal disease classification by reduced deep learning features. *Neural Computing and Applications*, 28(2), 329–334. <https://doi.org/10.1007/s00521-015-2059-9>
- Balodi, T. (2019, September 6). Convolutional Neural Network with Python Code Explanation | Convolutional Layer | Max Pooling in CNN. Retrieved November 27, 2023, from [www.analyticssteps.com website: https://www.analyticssteps.com/blogs/convolutional-neural-network-cnn-graphical-visualization-code-explanation](https://www.analyticssteps.com/blogs/convolutional-neural-network-cnn-graphical-visualization-code-explanation)
- Bidwai, P., Gite, S., Pahuja, K., & Kotecha, K. (2022). A Systematic Literature Review on Diabetic Retinopathy Using an Artificial Intelligence Approach. *Big Data and Cognitive Computing*, 6(4), 152. <https://doi.org/10.3390/bdcc6040152>

References

AGeeksforGeeks. (2019, August 5). CNN | Introduction to Pooling Layer. Retrieved November 27, 2023, from GeeksforGeeks website: <https://www.geeksforgeeks.org/cnn-introduction-to-pooling-layer/>

Hatice Öncel Çekim, Hatice Nur Karakavak, Gamze Özel, & Tekin, S. (2023). Earthquake magnitude prediction in Turkey: a comparative study of deep learning methods, ARIMA and singular spectrum analysis. *Environmental Earth Sciences*, 82(16). <https://doi.org/10.1007/s12665-023-11072-1>

Jacoba, C. M. P., Celi, L. A., & Silva, P. S. (2021). Biomarkers for Progression in Diabetic Retinopathy: Expanding Personalized Medicine through Integration of AI with Electronic Health Records. *Seminars in Ophthalmology*, 36(4), 250–257. <https://doi.org/10.1080/08820538.2021.1893351>

Kim, M., Kim, Y. N., Jang, M., Hwang, J., Kim, H.-K., Yoon, S. C., ... Kim, N. (2022). Synthesizing realistic high-resolution retina image by style-based generative adversarial network and its utilization. *Scientific Reports*, 12(1), 17307. <https://doi.org/10.1038/s41598-022-20698-3>

Lee, S. Y. (2023, November 6). Diabetic Retinopathy Screening- EyeWiki. Retrieved November 28, 2023, from eyewiki.aao.org website: https://eyewiki.aao.org/Diabetic_Retinopathy_Screening#:~:text=The%202018%20ICO%2FADA%20guidelines

Madala, S., Suvarna, V. K., & Pranathi Jalapally. (2022). Framework for Diabetic Retinopathy Classification. *Smart Innovation, Systems and Technologies*, 47–55. https://doi.org/10.1007/978-981-16-9669-5_4

Remidio. (n.d.). *Fundus on Phone FOP NM-10*. Retrieved from <https://www.remidio.com/fr/fundus-on-phone>

Vujosevic, S., Aldington, S. J., Silva, P., Hernández, C., Scanlon, P., Peto, T., & Simó, R. (2020). Screening for diabetic retinopathy: new perspectives and challenges. *The Lancet Diabetes & Endocrinology*, 8(4), 337–347. [https://doi.org/10.1016/s2213-8587\(19\)30411-5](https://doi.org/10.1016/s2213-8587(19)30411-5)

References

Diabetic Retinopathy Screening - EyeWiki. (n.d.). Eyewiki.aao.org. https://eyewiki.aao.org/Diabetic_Retinopathy_Screening

Goh, J. K. H., Cheung, C. Y., Sim, S. S., Tan, P. C., Tan, G. S. W., & Wong, T. Y. (2016). Retinal Imaging Techniques for Diabetic Retinopathy Screening. Journal of Diabetes Science and Technology, 10(2), 282–294. <https://doi.org/10.1177/1932296816629491>

Noriega, A., Meizner, D., Camacho, D., Enciso, J., Quiroz-Mercado, H., Morales-Canton, V., Almaatouq, A., & Pentland, A. (2020). Screening Diabetic Retinopathy Using an Automated Retinal Image Analysis System in Mexico: Independent and Assistive use Cases (Preprint). JMIR Formative Research. <https://doi.org/10.2196/25290>

UpToDate. (n.d.). www.uptodate.com. Retrieved November 29, 2023, from <https://www.uptodate.com/contents/diabetic-retinopathy-screening#:~:text=Initial%20screening%20can%20be%20accomplished>

Thank You

Do you have any questions?

CREDITS: This presentation template was created by [Slidesgo](#), and includes icons by [Flaticon](#) and infographics & images by [Freepik](#)